Study finds no beta-cell benefits with canakinumab, anakinra

04/17/2013 | Healio

Neither canakinumab nor anakinra fared better than placebo in delaying beta-cell dysfunction in patients with new-onset type 1 diabetes, a study in The Lancet found. Researchers also noted a greater prevalence of adverse events in patients who took anakinra compared with those in the placebo group.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN